BMY’s Amylin Purchase Advances Diabetes Franchise, Partnership with AZN

Bristol-Myers Squibb (NYSE:BMY) officially completed purchase of Amylin Pharmaceuticals (NASDAQ:AMLN) yesterday. The acquisition was completed without shareholder approval after BMY purchased additional AMLN shares directly from the company, making BMY the majority stakeholder. Outstanding shares were purchased at $31.00 each. (more…)